Organ dysfunction and failure in liver disease.

Acute-on-chronic liver failure (ACLF) is a complex syndrome defined by the existence of different organ failures (OFs) in patients with chronic liver disease, mainly cirrhosis. Several definitions have been proposed to define the syndrome, varying in the grade of the subjacent liver disease, the type of precipitants and the organs considered in the definition. Liver, coagulation, brain, kidney, circulatory and pulmonary are the six types of OFs proposed in the different classifications, with different prevalence worldwide. Irrespective of the definition used, patients who develop ACLF present a hyperactive immune system, profound haemodynamic disturbances and several metabolic alterations that finally lead to organ dysfunction. These disturbances are triggered by different factors such as bacterial infections, alcoholic hepatitis, gastrointestinal bleeding or hepatitis B virus flare, among others. Because patients with ACLF present high short-term mortality, a prompt recognition is needed to start treatment of the trigger event and specific organ support. Liver transplantation is also feasible in carefully selected patients and should be evaluated.

[1]  P. Kamath,et al.  AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients with Cirrhosis: Expert Review. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  K. Reddy,et al.  Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure , 2022, Alimentary pharmacology & therapeutics.

[3]  J. Trebicka,et al.  Pulmonary impairment independently determines mortality in critically ill patients with acute‐on‐chronic liver failure , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[4]  S. Caldwell,et al.  Haemostatic alterations and management of haemostasis in patients with cirrhosis. , 2022, Journal of hepatology.

[5]  S. Sarin,et al.  A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]. , 2022, Journal of hepatology.

[6]  N. Mahmud,et al.  Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database. , 2022, Journal of hepatology.

[7]  C. Gregoretti,et al.  ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure , 2021, European Respiratory Journal.

[8]  K. Reddy,et al.  The Prediction of In‐Hospital Mortality in Decompensated Cirrhosis with Acute‐on‐Chronic Liver Failure , 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[9]  P. Angeli,et al.  Acute-on-Chronic Liver Failure in Cirrhosis , 2021, Journal of clinical medicine.

[10]  E. Le Chatelier,et al.  Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. , 2021, Journal of hepatology.

[11]  W. Jiménez,et al.  Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. , 2021, Journal of hepatology.

[12]  C. Trautwein,et al.  Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study). , 2021, Journal of hepatology.

[13]  M. Karsdal,et al.  Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure , 2021, JHEP reports : innovation in hepatology.

[14]  B. Colsch,et al.  Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis. , 2021, Journal of hepatology.

[15]  F. Saliba,et al.  Intensive care management of acute-on-chronic liver failure. , 2021, Journal of hepatology.

[16]  Javier Fernández,et al.  Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. , 2021, Journal of hepatology.

[17]  G. Szabo,et al.  Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. , 2021, Journal of hepatology.

[18]  P. Thuluvath,et al.  EASL-CLIF criteria perform better than NACSELD to diagnose and prognosticate ACLF. , 2021, Journal of hepatology.

[19]  P. Cortesi,et al.  Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS). , 2021, Journal of hepatology.

[20]  R. Hernaez,et al.  Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis , 2021, Gut.

[21]  R. Moreau,et al.  The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis. , 2020, Journal of hepatology.

[22]  A. Ferruelo,et al.  Liver–lung interactions in acute respiratory distress syndrome , 2020, Intensive Care Medicine Experimental.

[23]  M. Manns,et al.  PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. , 2020, Journal of hepatology.

[24]  S. Taylor-Robinson,et al.  Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. , 2020, Journal of hepatology.

[25]  M. Trauner,et al.  Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. , 2020, Journal of hepatology.

[26]  N. Borruel,et al.  ALTERATIONS IN GUT MICROBIOME IN CIRRHOSIS AS ASSESSED BY QUANTITATIVE METAGENOMICS. RELATIONSHIP WITH ACUTE-ON-CHRONIC LIVER FAILURE AND PROGNOSIS. , 2020, Gastroenterology.

[27]  R. Moreau,et al.  Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment , 2020, JHEP reports : innovation in hepatology.

[28]  P. Angeli,et al.  Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome , 2020, Hepatology.

[29]  Q. Xie,et al.  The Use of NACSELD and EASL-CLIF Classification Systems of ACLF in the Prediction of Prognosis in Hospitalized Patients With Cirrhosis. , 2020, The American journal of gastroenterology.

[30]  D. J. Kim,et al.  Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. , 2020, Journal of hepatology.

[31]  A. Singal,et al.  Systematic review with meta‐analysis: liver transplant provides survival benefit in patients with acute on chronic liver failure , 2020, Alimentary pharmacology & therapeutics.

[32]  D. Gómez-Cabrero,et al.  Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. , 2020, Journal of hepatology.

[33]  R. Moreau,et al.  Cardiodynamic state is associated with systemic inflammation and fatal acute‐on‐chronic liver failure , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[34]  P. Kamath,et al.  Model for End‐Stage Liver Disease‐Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease , 2020, Hepatology.

[35]  B. Colsch,et al.  Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. , 2019, Journal of hepatology.

[36]  F. Wong Clinical Consequences of Infection in Cirrhosis: Organ Failures and Acute‐on‐Chronic Liver Failure , 2019, Clinical liver disease.

[37]  R. Jalan,et al.  Prognostic Role of Ammonia in Patients With Cirrhosis , 2019, Hepatology.

[38]  S. Liangpunsakul,et al.  Role of endotoxemia in causing renal dysfunction in cirrhosis , 2019, Journal of Investigative Medicine.

[39]  M. Mcphail,et al.  Lactate and number of organ failures predict intensive care unit mortality in patients with acute‐on‐chronic liver failure , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[40]  N. Mahmud,et al.  Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14‐Day Waitlist Mortality Than Status‐1a Patients , 2019, Hepatology.

[41]  Y. Chawla,et al.  Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update , 2019, Hepatology International.

[42]  Gavin D Perkins,et al.  Guidelines on the management of acute respiratory distress syndrome , 2019, BMJ Open Respiratory Research.

[43]  K. Reddy,et al.  Infections in Cirrhosis , 2019, Current Treatment Options in Gastroenterology.

[44]  M. Volk,et al.  Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation. , 2019, Gastroenterology.

[45]  S. Sarin,et al.  Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure , 2019, Hepatology.

[46]  J. Farrés,et al.  Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[47]  F. Nevens,et al.  Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[48]  I. Barjaktarevic,et al.  Acute Respiratory Failure and Pulmonary Complications in End-Stage Liver Disease , 2018, Seminars in Respiratory and Critical Care Medicine.

[49]  P. Kamath,et al.  Hepatorenal syndrome , 2018, Nature Reviews Disease Primers.

[50]  A. Sutton,et al.  Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis , 2018, Cochrane Database of Systematic Reviews.

[51]  J. Trebicka,et al.  EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. , 2018, Journal of hepatology.

[52]  Q. Ning,et al.  Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis , 2018, World journal of gastroenterology.

[53]  K. Reddy,et al.  NACSELD acute‐on‐chronic liver failure (NACSELD‐ACLF) score predicts 30‐day survival in hospitalized patients with cirrhosis , 2018, Hepatology.

[54]  S. Taylor-Robinson,et al.  Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial , 2017, Hepatology.

[55]  S. Jaber,et al.  Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3. , 2017, Journal of hepatology.

[56]  Jun Yu Li,et al.  Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure , 2017, Gut.

[57]  S. Keenan,et al.  Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure , 2017, European Respiratory Journal.

[58]  J. Daurès,et al.  Impact of acute‐on‐chronic liver failure on 90‐day mortality following a first liver transplantation , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[59]  P. Angeli,et al.  New diagnostic criteria and management of acute kidney injury. , 2017, Journal of hepatology.

[60]  J. Fallowfield,et al.  Systematic review with meta‐analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1 , 2017, Alimentary pharmacology & therapeutics.

[61]  R. Moreau,et al.  Acute-on-chronic liver failure: an update , 2017, Gut.

[62]  Richard Moreau,et al.  Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failure , 2016, Hepatology.

[63]  F. Nevens,et al.  Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. , 2016, Journal of hepatology.

[64]  D. Ganger,et al.  Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. , 2016, Gastroenterology.

[65]  S. Moestrup,et al.  Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). , 2016, Journal of hepatology.

[66]  R. Hirose,et al.  Simultaneous Liver–Kidney Allocation Policy: A Proposal to Optimize Appropriate Utilization of Scarce Resources , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[67]  Cindy X. Cai,et al.  Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. , 2015, Journal of critical care.

[68]  S. Sarin,et al.  AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis , 2015, Hepatology International.

[69]  Min Zheng,et al.  Acute‐on‐chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults , 2015, Hepatology.

[70]  A. de Gottardi,et al.  Clinical Course of acute‐on‐chronic liver failure syndrome and effects on prognosis , 2015, Hepatology.

[71]  F. Wong,et al.  Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation , 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[72]  R. Jalan,et al.  Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. , 2015, Journal of hepatology.

[73]  W. Kim,et al.  Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites , 2015, Gut.

[74]  R. Moreau,et al.  Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. , 2014, Journal of hepatology.

[75]  A. Gerbes,et al.  Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis , 2014, Gut.

[76]  K. Reddy,et al.  Survival in infection‐related acute‐on‐chronic liver failure is defined by extrahepatic organ failures , 2014, Hepatology.

[77]  D. Samuel,et al.  Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. , 2014, Journal of hepatology.

[78]  M. Pavesi,et al.  Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). , 2014, Journal of hepatology.

[79]  F. Bendtsen,et al.  Lactate metabolism in chronic liver disease , 2013, Scandinavian journal of clinical and laboratory investigation.

[80]  R. Moreau,et al.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.

[81]  Antonio Gasbarrini,et al.  Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: The RELIEF trial , 2013, Hepatology.

[82]  V. Paradis,et al.  Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[83]  J. Chen,et al.  Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. , 2013, World journal of gastroenterology.

[84]  P. Angeli,et al.  Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. , 2012, Journal of hepatology.

[85]  R. Jalan,et al.  Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. , 2012, Journal of hepatology.

[86]  Ulrich Treichel,et al.  Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. , 2012, Gastroenterology.

[87]  Samuel S. Lee,et al.  Mechanisms of TNFα-induced cardiac dysfunction in cholestatic bile duct-ligated mice: Interaction between TNFα and endocannabinoids , 2010 .

[88]  M. Peterson,et al.  Bedside Sublingual Video Imaging of Microcirculation in Assessing Bacterial Infection in Cirrhosis , 2009, Digestive Diseases and Sciences.

[89]  A. Sanyal,et al.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. , 2008, Gastroenterology.

[90]  V. Arroyo,et al.  Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. , 2008, Gastroenterology.

[91]  Vicente Arroyo,et al.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis , 2007, Postgraduate Medical Journal.

[92]  V. Arroyo,et al.  Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival , 2006, Hepatology.

[93]  J. Russell,et al.  Pathophysiology of Septic Shock. , 2018, Critical care clinics.

[94]  P. Angeli,et al.  Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. , 2017, Journal of hepatology.